Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...

FDA Approves CV Therapeutics, Inc Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial ...

ROCKVILLE, Md. The Food and Drug Administration has approved a supplemental approval application for a drug to treat chronic angina, the agency’s Division of Cardiovascular and Renal Products ...

SAN FRANCISCO — The first prospective international randomized controlled study focusing specifically on angina in patients with diabetes has shown that ranolazine (Ranexa, Gilead Sciences) is an ...

CV Therapeutics' approved product, Ranexa (R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other ...

Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...

PALO ALTO, Calif. The Food and Drug Administration has notified CV Therapeutics that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa, according to Reuters. Ranexa is ...

BOSTON (CBS.MW) -- In a setback for CV Therapeutics, a Food and Drug Administration advisory panel on Tuesday asked for more studies of the biotechnology firm's experimental treatment for a heart ...

The administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease. A collaborative study ...

CV Therapeutics is making progress in its pursuit of new indications for Ranexa, its angina drug for patients who haven't responded to other therapies. The agency agreed to consider its application to ...

Ranolazine is a novel antianginal agent that has also been shown to have electrophysiological properties in laboratory models. This is the first clinical evaluation of the antiarrythmic effects of ...

SAN FRANCISCO (MarketWatch) -- CV Therapeutics Inc. said late Wednesday that in a study Ranexa met the primary endpoint of reducing weekly angina frequency compared to placebo. Ranexa was ...